PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Gross profit decline while CRVO shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D change of 29.66% while CRVO maintains spending. Bruce Berkowitz would investigate effectiveness.
16.61%
G&A change of 16.61% while CRVO maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Operating expenses change of 25.48% while CRVO maintains costs. Bruce Berkowitz would investigate control.
25.48%
Total costs change of 25.48% while CRVO maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A change of 3.10% while CRVO maintains D&A. Bruce Berkowitz would investigate efficiency.
-28.10%
EBITDA decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-46.25%
EBITDA margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-27.47%
Operating income decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-45.52%
Operating margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-14.81%
Other expenses reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-27.92%
Pre-tax income decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-46.04%
Pre-tax margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Net income decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-46.04%
Net margin decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-20.00%
EPS decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
-20.00%
Diluted EPS decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
6.47%
Share count change of 6.47% while CRVO is stable. Bruce Berkowitz would verify approach.
6.47%
Diluted share change of 6.47% while CRVO is stable. Bruce Berkowitz would verify approach.